Bioaffinity Technologies, INC 8-K filings

bioAffinity Technologies' CyPath Lung test successfully guided a non-invasive surveillance strategy for an elderly patient with a suspicious lung nodule, avoiding an unnecessary biopsy.

BioAffinity Technologies, Inc. announced the posting of new investor presentation materials to its website for future management presentations.

BioAffinity Technologies announced the appointment of three nationally recognized pulmonary and lung cancer authorities to its Medical and Scientific Advisory Board to guide strategic priorities and CyPath Lung adoption.

BioAffinity Technologies, Inc. announced its 2026 Annual Meeting for April 30, 2026, and set a February 14, 2026, deadline for shareholder proposals.

BioAffinity Technologies' subsidiary, Precision Pathology Laboratory Services, successfully maintained its College of American Pathologists accreditation, reinforcing quality for its CyPath Lung test.

BioAffinity Technologies' subsidiary, Precision Pathology Laboratory Services, announces the transfer of 100% equity interest in Village Oaks Pathology Services from Dr. Roby P. Joyce to Dr. James Humphreys.

BioAffinity Technologies, Inc. adjourned its special stockholder meeting due to a lack of quorum, rescheduling it for January 19, 2026.

bioAffinity Technologies announced its CyPath Lung test successfully identified early-stage lung cancer in challenging cases, to be presented at the American Cancer Society National Lung Cancer Roundtable.

BioAffinity Technologies reported a 122% year-over-year increase in CyPath Lung testing revenue for Q3 2025, alongside a strategic shift from unprofitable pathology services.

bioAffinity Technologies announced significant month-over-month growth in CyPath Lung test volume, more than doubling since early 2025.

bioAffinity Technologies announced the Australian Patent Office accepted its patent application for a platform technology designed to detect and characterize multiple lung diseases.

BioAffinity Technologies will present research supporting its noninvasive CyPath Lung test for early lung cancer detection at the CHEST 2025 annual meeting.

bioAffinity Technologies announced a U.S. patent allowance for its AI-driven CyPath Lung diagnostic, enhancing its intellectual property for early-stage lung cancer detection.

bioAffinity Technologies has announced it has regained full compliance with Nasdaq's listing requirements, ensuring its common stock and warrants continue trading.

bioAffinity Technologies, Inc. completed a registered direct offering, raising approximately $1.8 million by selling 720,000 shares of common stock at $2.50 per share.

bioAffinity Technologies announced record sales for its CyPath Lung diagnostic test in the third quarter of 2025, driven by increased adoption in Veterans hospitals and mid-Atlantic market expansion.

BioAffinity Technologies successfully closed a $4.8 million public offering and regained compliance with Nasdaq listing requirements, including the minimum bid price and stockholders' equity.

bioAffinity Technologies will effect a 1-for-30 reverse stock split to comply with Nasdaq's minimum bid price requirement, effective September 18, 2025.

bioAffinity Technologies' CyPath Lung noninvasive diagnostic successfully identified lung cancer in a patient with difficult-to-diagnose ground-glass pulmonary nodules, shifting care from watchful waiting to immediate treatment.

BioAffinity Technologies, Inc. announced it will present updated company materials at the H.C. Wainwright 27th Annual Global Investment Conference.

bioAffinity Technologies' CyPath Lung test is highlighted in U.S. Medicine Magazine for its potential to improve lung cancer detection and reduce costs for the Department of Veterans Affairs.

BioAffinity Technologies, Inc. amended its May and August 2025 Warrants, increasing the Floor Price to $0.15 per share and reducing the number of shares issuable under the May 2025 Warrants.

BioAffinity Technologies appointed Roberto Rios, CPA, and Dr. John J. Oppenheimer to its Board of Directors, bringing significant financial and clinical expertise, while Gary Rubin resigned.

BioAffinity Technologies reported a 62% year-over-year increase in CyPath Lung testing revenue for the first half of 2025, despite an overall decrease in quarterly revenue due to strategic shifts.

BioAffinity Technologies completes a private placement and warrant inducement, raising $1.2 million and reclassifying $2.8 million in warrants to equity.

BioAffinity Technologies received a Nasdaq delisting notice due to non-compliance with minimum bid price and equity requirements, while simultaneously reporting a significant surge in CyPath Lung test sales.

bioAffinity Technologies' noninvasive CyPath Lung test successfully detected Stage 1A pulmonary mucinous adenocarcinoma in a high-risk individual, despite inconclusive traditional diagnostic methods.

bioAffinity Technologies' stockholders approved all seven proposals at the 2025 Annual Meeting, including the election of directors, ratification of auditors, a reverse stock split, and the issuance of shares related to warrants.

bioAffinity Technologies' CyPath Lung noninvasive sputum test successfully identified a Stage 1A neuroendocrine tumor in a patient, a cancer type missed by PET scans, bronchoscopies, and serum tumor markers.

bioAffinity Technologies announced the allowance of a Canadian patent for its CyPath Lung diagnostic, strengthening its intellectual property and opening market expansion opportunities in Canada.